{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T04:18:27Z","timestamp":1768623507659,"version":"3.49.0"},"reference-count":22,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int Forum Allergy Rhinol"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>This qualitative study assessed the experience of patients with chronic rhinosinusitis with nasal polyposis (NP) to inform the development of a novel symptom diary for clinical study use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Concept elicitation and cognitive interviews were conducted with patients who had a physician\u2010verified diagnosis of NP and a history of intranasal corticosteroid use. Concepts were identified via open\u2010ended and follow\u2010up questions. Relative symptom\/impact disturbance level was assessed using a scale of 0 (not at all disturbing) to 10 (extremely disturbing).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients (<jats:italic>n<\/jats:italic>\u00a0=\u00a030) attributed numerous symptoms and impacts to NP; the most prevalent and disturbing were nasal congestion (identified by 100% of patients; average disturbance rating\u00a0=\u00a07.9), nasal blockage\/obstruction (97%; 8.2), difficulty with sense of smell (97%; 7.6), facial pressure (90%; 6.2), postnasal drip (87%; 6.5), runny nose (87%; 6.2), facial pain (80%; 6.3), and headache (77%; 6.5). These symptoms, along with the impact of NP on sleep and daily activities, were included in the Nasal Polyposis Symptom Diary (NPSD). Cognitive interviews confirmed that patients understood the NPSD items and could select a response reflective of their experience at its worst over the past 24\u00a0hours using a four\u2010point scale (none, mild, moderate, or severe).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The most relevant and disturbing symptoms, according to patients with NP, were included in the NPSD. Interviews confirmed the suitability of NPSD in capturing the daily experience of patients. These findings support the content validity of the NPSD as a suitable tool for capturing NP symptoms and impacts.<\/jats:p><\/jats:sec>","DOI":"10.1002\/alr.22952","type":"journal-article","created":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T05:03:56Z","timestamp":1639803836000},"page":"996-1005","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Measuring the patient experience of chronic rhinosinusitis with nasal polyposis: qualitative development of a novel symptom diary"],"prefix":"10.1002","volume":"12","author":[{"given":"Sean","family":"O'Quinn","sequence":"first","affiliation":[{"name":"AstraZeneca  Gaithersburg MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian H.","family":"Shih","sequence":"additional","affiliation":[{"name":"AstraZeneca  Gaithersburg MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ubaldo J.","family":"Martin","sequence":"additional","affiliation":[{"name":"AstraZeneca  Gaithersburg MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oren","family":"Meyers","sequence":"additional","affiliation":[{"name":"IQVIA Real World Solutions, Patient Centered Solutions  New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Crooks","sequence":"additional","affiliation":[{"name":"IQVIA Real World Solutions, Patient Centered Solutions  New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Bailey","sequence":"additional","affiliation":[{"name":"IQVIA Real World Solutions, Patient Centered Solutions  New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley F.","family":"Slagle","sequence":"additional","affiliation":[{"name":"Aspen Consulting, LLC  Steamboat Springs CO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"issue":"29","key":"e_1_2_8_2_1","first-page":"1","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens WJ","year":"2020","journal-title":"Rhinology"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.otc.2016.08.006"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.55.suppl_2.S79"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02309-9"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2019.12.006"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00049"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2005.00725.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S290424"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/PROM.S156279"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.11.005"},{"key":"e_1_2_8_12_1","unstructured":"U.S. Food and Drug Administration Center for Drug Evaluation and Research Center for Devices and Radiological Health Center for Biologics Evaluation and Research.Guidance for Industry Patient\u2010Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Accessed December 24 2021.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/patient\u2010reported\u2010outcome\u2010measures\u2010use\u2010medical\u2010product\u2010development\u2010support\u2010labeling\u2010claims"},{"key":"e_1_2_8_13_1","unstructured":"U.S. Food and Drug Administration.FDA Patient\u2010Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient's Voice in Medical Product Development and Regulatory Decision Making. Accessed December 24 2021.https:\/\/www.fda.gov\/drugs\/development\u2010approval\u2010process\u2010drugs\/fda\u2010patient\u2010focused\u2010drug\u2010development\u2010guidance\u2010series\u2010enhancing\u2010incorporation\u2010patients\u2010voice\u2010medical"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.06.014"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.06.013"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00603.x"},{"key":"e_1_2_8_17_1","unstructured":"Patient\u2010Reported Outcomes and Quality of Life Database (PROQOLID) (Online). Mapi Research Institute. Accessed December 24 2021.https:\/\/eprovide.mapi\u2010trust.org\/about\/about\u2010proqolid."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03520250075037"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.2500\/105065895781808711"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2003.00420.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-4486.2009.01995.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.04.031"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.030"}],"container-title":["International Forum of Allergy &amp; Rhinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alr.22952","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/alr.22952","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alr.22952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T22:12:50Z","timestamp":1692828770000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/alr.22952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1002\/alr.22952"],"URL":"https:\/\/doi.org\/10.1002\/alr.22952","archive":["Portico"],"relation":{},"ISSN":["2042-6976","2042-6984"],"issn-type":[{"value":"2042-6976","type":"print"},{"value":"2042-6984","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]},"assertion":[{"value":"2021-07-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}